140 related articles for article (PubMed ID: 16682734)
1. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
Calvo E; Baselga J
J Clin Oncol; 2006 May; 24(14):2158-63. PubMed ID: 16682734
[TBL] [Abstract][Full Text] [Related]
2. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
3. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
4. An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer.
Edelman MJ
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S3-8. PubMed ID: 16459173
[TBL] [Abstract][Full Text] [Related]
5. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.
Jänne PA
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S9-15. PubMed ID: 16459174
[TBL] [Abstract][Full Text] [Related]
6. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
Wong KK
Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
[TBL] [Abstract][Full Text] [Related]
7. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
8. Impact of EGFR mutation analysis in non-small cell lung cancer.
Yamamoto H; Toyooka S; Mitsudomi T
Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
[TBL] [Abstract][Full Text] [Related]
9. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor mutations in lung cancer.
Sharma SV; Bell DW; Settleman J; Haber DA
Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
[TBL] [Abstract][Full Text] [Related]
11. [Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
Zhou CC; Deng XF
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):138-40. PubMed ID: 17445479
[No Abstract] [Full Text] [Related]
12. The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results.
Tsao AS; Papadimitrakopoulou V
Clin Lung Cancer; 2013 Jul; 14(4):311-21. PubMed ID: 23582282
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues.
Bencardino K; Manzoni M; Delfanti S; Riccardi A; Danova M; Corazza GR
Intern Emerg Med; 2007 Mar; 2(1):3-12. PubMed ID: 17551677
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of growth factor signalling.
Wakeling AE
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S183-7. PubMed ID: 16113095
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.
Nomura M; Shigematsu H; Li L; Suzuki M; Takahashi T; Estess P; Siegelman M; Feng Z; Kato H; Marchetti A; Shay JW; Spitz MR; Wistuba II; Minna JD; Gazdar AF
PLoS Med; 2007 Apr; 4(4):e125. PubMed ID: 17455987
[TBL] [Abstract][Full Text] [Related]
16. [EGFR pathway and mechanism of action of tyrosine kinase inhibitors].
Zalcman G
Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S5-6. PubMed ID: 17242635
[No Abstract] [Full Text] [Related]
17. Lung cancer in never smokers: change of a mindset in the molecular era.
Lee YJ; Kim JH; Kim SK; Ha SJ; Mok TS; Mitsudomi T; Cho BC
Lung Cancer; 2011 Apr; 72(1):9-15. PubMed ID: 21272954
[TBL] [Abstract][Full Text] [Related]
18. Race, gender and mutations in the prediction of anti-EGFR activity.
Jimeno A
Future Oncol; 2005 Apr; 1(2):201-4. PubMed ID: 16555991
[TBL] [Abstract][Full Text] [Related]
19. A review of EGFR targeted therapy.
Baselga J
Clin Adv Hematol Oncol; 2003 Apr; 1(4):218-9. PubMed ID: 16224409
[No Abstract] [Full Text] [Related]
20. Targeted treatment tested as potential cancer cure.
Hayden EC
Nature; 2011 Nov; 479(7373):281. PubMed ID: 22094668
[No Abstract] [Full Text] [Related]
[Next] [New Search]
